Unlock instant, AI-driven research and patent intelligence for your innovation.

Composition for culturing t cells and method for culturing t cells using same

A composition and cell technology, applied in the field of T cell culture, to achieve the effect of increasing proliferation and activity, and safe preparation

Pending Publication Date: 2022-07-29
GI CELL INC
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, it is also possible to generate new HIV viruses in previously HIV-positive patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for culturing t cells and method for culturing t cells using same
  • Composition for culturing t cells and method for culturing t cells using same
  • Composition for culturing t cells and method for culturing t cells using same

Examples

Experimental program
Comparison scheme
Effect test

preparation Embodiment 1

[0160] Preparation Example 1, hCD80-Fc-IL-2 variant (2M): preparation of GI101

[0161] To generate a fusion protein containing a human CD80 fragment, an Fc domain and an IL-2 variant, a polynucleotide comprising the nucleotide sequence (SEQ ID NO: 8) was synthesized by ThermoFisher Scientific's Invitrogen GeneArt Gene Synthesis service from the N-terminal Encoding sequence containing signal peptide (SEQ ID NO:1), CD80 fragment (SEQ ID NO:2), linker-bound Ig hinge (SEQ ID NO:3), Fc domain (SEQ ID NO:4), linker ( SEQ ID NO: 5) and a fusion protein of IL-2 variant (2M) (SEQ ID NO: 6) with two amino acid substitutions (R38A, F42A) and cloned into the pcDNA3_4 vector. In addition, this vector was introduced into CHO cells (Expi-CHO TM ), used to express the fusion protein with SEQ ID NO:9. After introduction of the vector, the CHO cell culture solution was incubated at 37°C, 125RPM and 8% CO 2 cultured for 7 days, and then harvested to purify the fusion protein. The purified f...

preparation Embodiment 2

[0164]Preparation Example 2, Fc-IL-2 variant (2M) dimer: Preparation of Fc-IL-2v2

[0165] To generate a fusion protein containing the Fc domain and the IL-2 variant, a polynucleotide comprising the nucleotide sequence (SEQ ID NO: 45), in order from the N-terminus, was synthesized by ThermoFisher Scientific's Invitrogen GeneArt Gene Synthesis service The encoding contains a signal peptide (SEQ ID NO: 1), an Ig hinge (SEQ ID NO: 38), an Fc domain (SEQ ID NO: 4), a linker (SEQ ID NO: 5) and has two amino acid substitutions (R38A, F42A) fusion protein of IL-2 variant (2M) (SEQ ID NO: 6) and cloned into pcDNA3_4 vector. In addition, this vector was introduced into CHO cells (Expi-CHO TM ), used to express the fusion protein with SEQ ID NO:44. After introduction of the vector, the CHO cells were incubated at 37°C, 125 RPM and 8% CO 2 cultured for 7 days, and cells were harvested to purify fusion protein dimers. The purified fusion protein dimer was named "Fc-IL2v2".

[0166] P...

preparation Embodiment 3

[0167] Preparation Example 3, Fc-IL-2 dimer: Preparation of Fc-IL-2wt

[0168] In order to generate a fusion protein containing the Fc domain and wild-type IL-2, a polynucleotide comprising the nucleotide sequence (SEQ ID NO: 43) was synthesized by ThermoFisher Scientific's Invitrogen GeneArt Gene Synthesis service, which sequentially encodes from the N-terminal Signal peptide (SEQ ID NO:1), Ig hinge (SEQ ID NO:38), Fc domain (SEQ ID NO:4), linker (SEQ ID NO:5) and wild-type IL-2 (SEQ ID NO:38) 10) and cloned into the pcDNA3_4 vector. In addition, this vector was introduced into CHO cells (Expi-CHO TM ), used to express the fusion protein with SEQ ID NO:42. After introduction of the vector, the CHO cells were incubated at 37°C, 125 RPM and 8% CO 2 cultured for 7 days, and then harvested to purify the fusion protein dimer. The purified fusion protein dimer was named "Fc-IL2wt".

[0169] Purification and collection of the fusion protein were performed using the same method ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a composition for proliferating T cells comprising a fusion protein dimer containing an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and a method for culturing T cells using the same. The T cells cultured by the invention can increase the proliferation and activity of the T cells without using CD3 / CD28 antibody-bound magnetic beads. Furthermore, peripheral blood mononuclear cells of a patient are cultured to proliferate T cells, so that the T cells are not afraid of human side effects, and thus the T cells can be widely used as a novel T cell therapeutic agent. In addition, the CD8 + T cells cultured above have increased activity, providing a more effective therapeutic agent.

Description

technical field [0001] The present invention relates to a composition for culturing T cells comprising a fusion protein comprising a CD80 protein and IL-2 wild type or a variant thereof, and a T cell culturing method using the same. Background technique [0002] Novartis' Kymriah (INN: Tisagenlecleucel, product code: CTL019), recently approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), is a genetically modified autologous A gene therapy agent composed of T cells (US Patent No. 9,499,629). The product is produced by transduction of a patient's own T cells with a lentiviral vector encoding a chimeric antigen receptor (CAR) for human CD19. The action of this T cell is antigen-dependent and specifically targets and destroys CD19-positive B cells in a manner independent of the major histocompatibility complex. [0003] Kymriah is manufactured as follows: T cells are proliferated through two distinct processes, the proliferated T cells ar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N5/0783
CPCC12N5/0636C12N2501/2302C12N2501/51C07K14/70532C07K14/55C07K2319/30C12N5/06C12N2506/115
Inventor 张明浩洪天杓崔荣周李俊燮
Owner GI CELL INC